Borregaard ASA (BRGAY) Q2 2026 Earnings Call Transcript

Borregaard reported Q2 2026 EBITDA of NOK 515m, slightly below NOK 522m a year ago, despite generally solid underlying operations. Results were pressured by higher energy, logistics, and chemical costs (partly offset by lower wood costs) and included a NOK 337m impairment on its Alginor investment. Net currency effects were slightly positive, but the impairment and cost headwinds likely weigh on near-term sentiment.

Analysis

The setup is less about the quarter itself than about margin elasticity. Borregaard is still proving it can run a differentiated bio-based business, but the cost stack is now the gating factor: if energy, logistics and chemical inputs stay sticky, the company has limited near-term ability to fully reprice without losing mix. That makes the next 1-2 quarters a test of operating leverage rather than demand growth; any disappointment will likely show up first in EBITDA margin, not revenue.

The write-down on Alginor matters because it signals a tighter capital-allocation regime in a part of the story that had been valued on optionality. That is good for discipline, but it also lowers the probability that investors get paid for a sprawling bioeconomy platform narrative. Second-order, this is a negative read-through for small, pre-profit Nordic circular-bio names that rely on cheap financing and strategic patience; funding standards are likely getting stricter, which can compress multiples over the next 6-18 months.

Contrarian view: the market may over-penalize a non-core impairment and miss that lower wood costs plus FX provide a partial buffer. If European power and freight roll over, the earnings reset could reverse quickly, so this is not a structural short unless input inflation persists. The thesis is falsified if Q3 shows clean margin recovery or if management explicitly quantifies a low-risk exit from Alginor with no further capital drag.

Key Decisions for Investors

• Underweight/short BRGAY on any post-call bounce; 1-3 month horizon, with the trade working if input-cost pressure keeps EBITDA margins below the recent run-rate. Cover if management shows sequential margin expansion or if European energy costs fall materially.
• Pair trade: short BRGAY vs long XLB to isolate company-specific margin and impairment risk from broad chemical beta. Target 5-8% relative underperformance over the next 1-2 quarters; stop if BRGAY re-rates on lower cost inputs or improved mix.
• Watch-list alert on European gas, freight, and chemical feedstock indices: if they normalize faster than expected, the current negative setup should be unwound because the company’s pricing power is strong enough to recover margins with a lag.
• Do not allocate fresh capital to small-cap bioeconomy or marine-bio names until the market has digested this impairment cycle; Borregaard is signaling that adjacent-optionality is now being priced with a much higher discount rate.